trichostatin A

Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.

Cross Reference

Introduction

To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with trichostatin A?

trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with trichostatin A

MeSH term MeSH ID Detail
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Breast Neoplasms D001943 24 associated lipids
Neoplasms D009369 13 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Carcinoma D002277 18 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Brain Neoplasms D001932 15 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Melanoma D008545 69 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Asthma D001249 52 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Intellectual Disability D008607 13 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Endometriosis D004715 29 associated lipids
Uterine Neoplasms D014594 18 associated lipids
Adrenoleukodystrophy D000326 29 associated lipids
Prostatic Hyperplasia D011470 20 associated lipids
Alzheimer Disease D000544 76 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Leukemia D007938 74 associated lipids
Neuroblastoma D009447 66 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Myeloproliferative Disorders D009196 5 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Fibrosis D005355 23 associated lipids
Carcinoma, Ductal, Breast D018270 19 associated lipids
Carcinoma, Renal Cell D002292 12 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Leukemia, Promyelocytic, Acute D015473 3 associated lipids
Stroke D020521 32 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Per page 10 20 50 100 | Total 139

PubChem Associated disorders and diseases

What pathways are associated with trichostatin A

Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with trichostatin A?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with trichostatin A?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with trichostatin A?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with trichostatin A?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with trichostatin A?

Mouse Model

Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).

Xenograft Model

Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).

Cancer Model

Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with trichostatin A

Download all related citations
Per page 10 20 50 100 | Total 3126
Authors Title Published Journal PubMed Link
Fan J et al. Expression and function of CD9 in melanoma cells. 2010 Mol. Carcinog. pmid:19777564
Osada H et al. Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines. 2005 Mol. Carcinog. pmid:16163707
Xiong H et al. Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. 2012 Mol. Carcinog. pmid:21520296
Glaser KB et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. 2003 Mol. Cancer Ther. pmid:12589032
Rahman R et al. Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells. 2010 Mol. Cancer Ther. pmid:20643785
Dowdy SC et al. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. 2006 Mol. Cancer Ther. pmid:17121923
Saunders LR and Verdin E Ornithine decarboxylase activity in tumor cell lines correlates with sensitivity to cell death induced by histone deacetylase inhibitors. 2006 Mol. Cancer Ther. pmid:17121924
Kim J et al. PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells. 2010 Mol. Cancer Ther. pmid:20571067
Strait KA et al. Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. 2002 Mol. Cancer Ther. pmid:12479699
Blagosklonny MV et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. 2002 Mol. Cancer Ther. pmid:12481415
Alao JP et al. Inhibition of type I histone deacetylase increases resistance of checkpoint-deficient cells to genotoxic agents through mitotic delay. 2009 Mol. Cancer Ther. pmid:19723888
Chung YL et al. Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. 2004 Mol. Cancer Ther. pmid:15026552
Francia G et al. Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents. 2005 Mol. Cancer Ther. pmid:16227397
Sonnemann J et al. Serine proteases in histone deacetylase inhibitor-induced apoptosis. 2010 Mol. Cancer Ther. pmid:20682651
Moiseeva EP et al. Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. 2007 Mol. Cancer Ther. pmid:18025290
García-Morales P et al. Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. 2005 Mol. Cancer Ther. pmid:16093438
Nome RV et al. Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death. 2005 Mol. Cancer Ther. pmid:16093439
Danam RP et al. Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins. 2005 Mol. Cancer Ther. pmid:15657354
Lee JH et al. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. 2006 Mol. Cancer Ther. pmid:17172411
Scott GK et al. Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. 2002 Mol. Cancer Ther. pmid:12477051
De los Santos M et al. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. 2007 Mol. Cancer Ther. pmid:17431121
Muscolini M et al. Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. 2008 Mol. Cancer Ther. pmid:18566213
Ma X et al. Identification of LIV1, a putative zinc transporter gene responsible for HDACi-induced apoptosis, using a functional gene screen approach. 2009 Mol. Cancer Ther. pmid:19887557
Miyanaga A et al. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. 2008 Mol. Cancer Ther. pmid:18606719
Sun F et al. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. 2009 Mol. Cancer Ther. pmid:19934278
Roy S et al. Array-based analysis of the effects of trichostatin A and CG-1521 on cell cycle and cell death in LNCaP prostate cancer cells. 2008 Mol. Cancer Ther. pmid:18645003
Strait KA et al. Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. 2005 Mol. Cancer Ther. pmid:15827334
Ostapkowicz A et al. Lipid rafts remodeling in estrogen receptor-negative breast cancer is reversed by histone deacetylase inhibitor. 2006 Mol. Cancer Ther. pmid:16505096
Hellebrekers DM et al. Angiostatic activity of DNA methyltransferase inhibitors. 2006 Mol. Cancer Ther. pmid:16505122
Jeon HW and Lee YM Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression. 2010 Mol. Cancer Ther. pmid:20442303
Rokhlin OW et al. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. 2006 Mol. Cancer Res. pmid:16513842
Gaymes TJ et al. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? 2006 Mol. Cancer Res. pmid:16877702
Wischnewski F et al. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. 2006 Mol. Cancer Res. pmid:16687489
Link PA et al. Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells. 2009 Mol. Cancer Res. pmid:19531572
Fan T et al. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. 2011 Mol. Cancer Res. pmid:21383005
Pan J et al. TLS-ERG leukemia fusion protein deregulates cyclin-dependent kinase 1 and blocks terminal differentiation of myeloid progenitor cells. 2008 Mol. Cancer Res. pmid:18505930
Kim M et al. Epigenetic down-regulation and suppressive role of DCBLD2 in gastric cancer cell proliferation and invasion. 2008 Mol. Cancer Res. pmid:18314483
Ko JM et al. Monochromosome transfer and microarray analysis identify a critical tumor-suppressive region mapping to chromosome 13q14 and THSD1 in esophageal carcinoma. 2008 Mol. Cancer Res. pmid:18403638
Liu PY et al. Modulation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by Zac1 through the antagonistic regulators p53 and histone deacetylase 1 in HeLa Cells. 2008 Mol. Cancer Res. pmid:18644983
Hu J and Colburn NH Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. 2005 Mol. Cancer Res. pmid:15755876
Alimirah F et al. IFI16 in human prostate cancer. 2007 Mol. Cancer Res. pmid:17339605
Lee JH et al. Notch signal activates hypoxia pathway through HES1-dependent SRC/signal transducers and activators of transcription 3 pathway. 2009 Mol. Cancer Res. pmid:19808903
Sharma P et al. Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. 2010 Mol. Cancer pmid:20609221
Li Y et al. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer. 2013 Mol. Cancer pmid:23379261
Li S et al. Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis. 2011 Mol. Cancer pmid:21314984
Lynch CA et al. Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation. 2002 Mol. Cancer pmid:12234381
Hudson RS et al. Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer. 2013 Mol. Cancer pmid:23409773
Puca R et al. HIPK2 modulates p53 activity towards pro-apoptotic transcription. 2009 Mol. Cancer pmid:19828042
Röhrs S et al. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia. 2009 Mol. Cancer pmid:19835597
Kuljaca S et al. Enhancing the anti-angiogenic action of histone deacetylase inhibitors. 2007 Mol. Cancer pmid:17958916